← All trials
NCT02298088
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2015
- Primary completion
- Aug 1, 2017
- Completion date
- Aug 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 3794
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Hospital do CoracaoLead sponsor
- Hospital do CoracaoStudy chair
- Duke UniversityStudy chair
- Canadian Heart Research CentreStudy chair
- Cayetano Heredia UniversityStudy chair
- Hospital e Maternidade Celso PierroStudy chair
- Investigación Independiente S.A.Study chair
- South Australian Health and Medical Research InstituteStudy chair
- Clinical Hospital #15 Clinical Hospital #15 named after O.M.Filatov, Moscow, RussiaStudy chair
- Chinese Academy of Medical SciencesStudy chair
- University of Sao PauloStudy chair
- University of AucklandStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.